Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

Background Immune checkpoint therapy (ICT) has low response rates in patients with metastatic castration-resistant prostate cancer (mCRPC), in part due to few T cells in the tumor microenvironment (TME). Anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) promotes intratumoral T cell infiltrat...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Hong Chen, Padmanee Sharma, James P Allison, Sumit K Subudhi, Sonali Jindal, Sreyashi Basu, Bilal A Siddiqui, Paul G Corn, Ana M Aparicio, Shalini S Yadav, Rebecca S S Tidwell, Ashwin Varma, Christopher J Logothetis
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMJ Publishing Group 2021-10-01
Saila:	Journal for ImmunoTherapy of Cancer
Sarrera elektronikoa:	https://jitc.bmj.com/content/9/10/e002919.full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!